All In Biotech

Drug Trial Radar · NCT05312021

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction

Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction: a Safety and Efficacy Phase 2 Randomized Clinical Study (SP9In-HFpEF)

Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Apr 2022

Primary completion

Sep 2023

Study completion Nov 2023

Sponsor

Sponsor type
Industry
Collaborators
Imara, Inc.
First posted
Apr 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF). The primary objective is to evaluate whether IMR-687 reduces NT-proBNP compared to placebo in these patients.

Conditions

  • Heart Failure With Preserved Ejection Fraction

Interventions

  • IMR-687Drug

    150 mg and 200 mg tablets

  • IMR-687 PlaceboOther

    Matching placebo to IMR-687

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in NT-proBNPTime frame: Baseline to Week 16

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.